ACRS

ATI-450

Rheumatoid Arthritis

Phase 2a

Exp Date

H1 2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: ATI-450 for Rheumatoid Arthritis Phase 2a Clinical Trial


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 2a Readout


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • H1 2021


PRIOR DATA
PRESS RELEASES

MECHANISM OF ACTION

ATI-450 is an investigational oral small molecule inhibitor of the p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) inflammatory signaling pathway. This pathway drives the expression of multiple cytokines, chemokines, matrix metalloproteases and other inflammatory signals. Key inflammatory cytokines driven by this pathway include tumor necrosis factor α (TNFα), interleukin-1α and -1β (IL1α and IL1β), and interleukin-6 (IL6). On the basis of this mechanism, Aclaris is developing ATI-450 as a potential treatment for immuno-inflammatory diseases.

Updated by MV

#ATI450 #Rheumatoidarthritis #ACRS #autoimmunedisease #inflammatorydisease

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon